Guanosine 3'-5'-Monophosphate in the CSF of Neurological Patients
- 1 January 1977
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 34 (1), 12-13
- https://doi.org/10.1001/archneur.1977.00500130032006
Abstract
• Cyclic guanosine monophosphate (cGMP) levels have been measured in the cerebrospinal fluid of patients with various neurological diseases. The subjects with epilepsy or cerebrovascular diseases do not show any difference from the controls. Moreover, in the CSF of patients having cerebral tumors the levels of cGMP are markedly increased. This change is in line with previous in vitro studies on the increase of cGMP during cell growth and cell proliferation showing that the role of the nucleotide is important for the control of the life cycle of the cell.This publication has 4 references indexed in Scilit:
- Plasma membrane-associated increase in guanylate cyclase activity in regenerating rat liverNature, 1975
- Increased particulate and decreased soluble guanylate cyclase activity in regenerating liver, fetal liver, and hepatoma.Proceedings of the National Academy of Sciences, 1975
- Simultaneous isolation of adenosine 3′,5′-cyclic monophosphate (cAMP) and guanosine 3′,5′-cyclic monophosphate (cGMP) in small tissue samplesAnalytical Biochemistry, 1974
- Pleiotypic Control by Cyclic AMP: Interaction with Cyclic GMP and Possible Role of MicrotubulesProceedings of the National Academy of Sciences, 1973